Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
The spectrum and potency of ciprofloxacin, gatifloxacin and levofloxacin was compared to that of 10 other agents against urinary tract isolates of Pseudomonas aeruginosa among patients in the year 2000 SENTRY Antimicrobial Surveillance Program (Europe, Latin America, North America). Dramatic differences were observed between isolates in geographic areas with the most fluoroquinolone-resistant strains detected in Latin America (54.5% resistance) compared to resistance rates of 40.8-43.7% and 28.3-29.2% for Europe and North America, respectively. Overall, no significant differences were observed between the spectrums of these fluoroquinolones (37.1-38.8% resistance) for therapy of P. aeruginosa urinary tract infections in hospitalized patients. Generally, in this world wide sample, aminoglycosides, carbapenems (imipenem, meropenem), cefepime, and piperacillin with or without tazobactam possessed a wider range of activity and spectrum versus current P. aeruginosa clinical isolates.
Jones
R N
RN
The JONES Group/JMI Laboratories, North Liberty, Iowa, USA. ronald-jones@imilabs.com
Beach
M L
ML
Pfaller
M A
MA
D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D005060:Europe; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D006801:Humans; D007769:Lactams / Q000494:pharmacology; D007843:Latin America; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D009656:North America; D015242:Ofloxacin / Q000494:pharmacology*; D011159:Population Surveillance; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D012041:Regional Medical Programs; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary; D024841:Fluoroquinolones; D007769:Lactams; D002939:Ciprofloxacin; D064704:Levofloxacin; D015242:Ofloxacin; D000077734:Gatifloxacin